However, a notable deficiency persists in terms of pharmacological interventions that specifically target the FUS–DDIT3 fusion protein, which represents a characteristic molecular alteration in MLS. The gene discussed is DDIT3; the disease is McLeod neuroacanthocytosis syndrome.